Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
by on Friday, July 6th, 2012 | No Comments
Condition: Castration-resistant Prostate Cancer
Interventions: Drug: BEZ235; Drug: BKM120; Drug: BEZ235; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting – verified July 2012
Originally posted here: Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients